Summary of trials, by design characteristics
| Trial subtype | ||||
| Trials | No of patients | Female proportion | Age | |
| Invasive procedure/surgery | 13 | 6852 | 21.1 (19.9–25.3) | 64.7 (60.5–69.8) |
| Device trials | 30 | 26 328 | 23.6 (19.4–27.4) | 64.9 (63.5–66.4) |
| Drug trials | 79 | 180 080 | 26.9 (21.9–40.1) | 66.3 (62.8–70) |
| Outpatient care | 18 | 19 589 | 29.7 (22.8–41.7) | 66.3 (63.6–70.9) |
| Diagnostic trials | 10 | 7384 | 39.4 (32.6–48.8) | 74 (63.1–77) |
| Older participants | 5 | 4449 | 40.5 (37.0–55.1) | 76 (76–76.5) |
| All invasive/procedural* | 40 | 30 680 | 23.3 (18.2–26.8) | 64.9 (62.8–66.8) |
| All non-invasive | 106 | 208 133 | 28.8 (22–40.5) | 66.3 (63–70) |
| All trials | 146 | 238 813 | 25.8 (21.3–36.0) | 66 (63–69.5) |
Age shown as median (IQR). Note some trials fit into more than one category, for example, device and outpatient care; medication and older participant. Invasive procedure—including percutaneous coronary intervention, intra-aortic balloon pump, impella, mitraclip, ablation trials. Outpatient care—for example, remote monitoring, outpatient HF follow up and education trials. Diagnosis—for example, early use of BNP, use of HF risk scores on admission, care bundle trials. Older participants—minimum age 45 (1 trial), 60 (1 trial), 70 (2 trials) and 75 (1 trial).
*Including any invasive coronary, valvular, surgical or device insertion procedure.
BNP, B-type natriuretic peptide; HF, heart failure.